Open an account

Corbus Pharmaceuticals Holdings

CRBP · NASDAQ

$4.42−$0.04 (−0.90%)TodayMarket closed ·
Prev close $4.46

About CRBP

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. The company is headquartered in Norwood, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2014-10-24. The firm has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

Employees
36
Headquarters
Norwood, Massachusetts
Listed
Oct 24, 2014
Sector
Health Care
Industry
Biotechnology
Website
corbuspharma.com

CRBP key statistics

Market cap
85.49M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
849.85K
Volume
477.66K
Open price
$4.48
High today
$4.68
Low today
$4.41
52 Week high
$20.56
52 Week low
$4.22

Corbus Pharmaceuticals Holdings (CRBP) at a glance

Corbus Pharmaceuticals Holdings (CRBP) last traded at $4.42, with a market cap of 85.49M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.41 and $4.68. The current price is 0.3% above the day's low and 5.6% below its high.

Volume so far is 477.66K shares, below the average of 849.85K shares a day.

Over the past year Corbus Pharmaceuticals Holdings has ranged from $4.22 to $20.56, and now sits 1% of the way up that range.

Corbus Pharmaceuticals Holdings met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$1.81 per share against an estimate of -$1.28.

The average analyst price target is $36.61, 728.2% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 7 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 11 analystsAvg $36.61
Low
$28.28
Now
$4.42
High
$50.40

CRBP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 17.4% on average.

  1. Q3 FY24: reported -$1.15 per share against an estimate of -$0.971
  2. Q4 FY24: reported -$0.78 per share against an estimate of -$1.29
  3. Q1 FY25: reported -$1.39 per share against an estimate of -$1.31
  4. Q2 FY25: reported -$1.44 per share against an estimate of -$1.54
  5. Q3 FY25: reported -$1.90 per share against an estimate of -$1.74
  6. Q4 FY25: reported -$1.25 per share against an estimate of -$1.61
  7. Q1 FY26: reported -$1.23 per share against an estimate of -$1.24
  8. Q2 FY26: reported -$1.81 per share against an estimate of -$1.28

CRBP news

  • Vandana Singh

    Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'

  • Market-Moving News for September 14th

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

Similar companies

Companies in the same industry as Corbus Pharmaceuticals Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.